Endocrinology Drugs Market Report 2025

The endocrinology drugs market size has declined marginally in recent years. It will grow from $26.29 billion in 2024 to $26.2 billion in 2025 at a compound annual growth rate (CAGR) of -0.3%. The growth in the historic period can be attributed to increasing prevalence of diabetes globally, increasing government initiatives, increasing healthcare expenditure, increasing prevalence of adrenal gland disorders, a rise in demand for insulin analogs, and growth in the number of endocrinologists.

The endocrinology drugs market size is expected to see marginal growth in the next few years. It will grow to $26.37 billion in 2029 at a compound annual growth rate (CAGR) of 0.2%. The growth in the forecast period can be attributed to a growing diabetic population, increasing prevalence of endocrine disorders, a growing number of adolescents with hormonal imbalances, and rising obesity rates. Major trends in the forecast period include technological advancements, adoption of advanced drug delivery systems, integration of digital health solutions, precision medicine, and combination therapies.

The forecast of 0.2% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade restrictions could hinder U.S. hormone therapy access by inflating prices of recombinant insulin analogs and thyroid medication active pharmaceutical ingredients imported from France and India, resulting in delayed diabetes management and higher chronic disease treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of endocrine diseases is driving the growth of the endocrinology drugs market. Endocrine diseases are disorders that affect the endocrine system, leading to imbalances in hormone production or regulation, which disrupt normal bodily functions. Factors contributing to the increasing prevalence of endocrine diseases include lifestyle changes, an aging population, and improvements in diagnostic methods, which have all led to greater recognition and incidence of these conditions. Endocrinology drugs are designed to manage these diseases by regulating hormone levels, addressing glandular dysfunction, and restoring hormonal balance, thus improving health outcomes. For example, in May 2023, the National Library of Medicine reported that approximately 13 million people in the U.S. (about 4.78% of the population) suffer from undiagnosed endocrine disorders, with thyroid disease being one of the most prevalent, affecting 30% to 40% of patients treated in endocrine practices. This growing prevalence of endocrine diseases is significantly driving the demand for endocrinology drugs.

Leading companies in the endocrinology drugs market are prioritizing the development of innovative products, such as ready-to-use vials, to enhance medication administration. These pre-filled and pre-dosed containers eliminate the need for reconstitution or preparation before use. For example, in December 2022, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, introduced Levothyroxine sodium injection in ready-to-use vials with a concentration of 100 mcg/mL. This formulation is designed for immediate application, reducing the risk of preparation errors and enhancing patient safety. It ensures precise and consistent dosing, which is essential for treating conditions such as hypothyroidism and myxedema coma. Additionally, these vials improve efficiency for healthcare providers by saving time and ensuring accurate administration in urgent care scenarios.

In July 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Amolyt Pharma Inc., a France-based company specializing in therapies for rare endocrine diseases. This acquisition is aimed at strengthening AstraZeneca’s portfolio in rare endocrine diseases by integrating Amolyt Pharma's innovative pipeline of late-stage therapies. This move highlights the ongoing efforts by major pharmaceutical companies to expand their capabilities and offerings in the growing market for endocrinology drugs.

Major players in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited.

North America was the largest region in the endocrinology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in endocrinology drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the endocrinology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The endocrinology drugs market consists of sales of insulin analogs, antithyroid drugs, and anti-diabetic drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The endocrinology drugs market research report is one of a series of new reports that provides endocrinology drugs market statistics, including endocrinology drugs industry global market size, regional shares, competitors with an endocrinology drugs market share, detailed endocrinology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the endocrinology drugs industry. This endocrinology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Endocrinology drugs are pharmaceutical treatments designed to manage and regulate disorders associated with the endocrine system, which includes glands such as the thyroid, pancreas, and adrenal glands. These drugs are used to treat conditions such as diabetes, thyroid disorders, growth hormone deficiencies, and hormonal imbalances, aiming to restore normal hormonal levels and improve the overall function of the endocrine system.

The primary conditions treated with endocrinology drugs include hyperthyroidism, hypothyroidism, diabetes, polycystic ovarian syndrome, growth hormone disorders, and pituitary gland disorders, among others. Hyperthyroidism, for example, is marked by an overproduction of thyroid hormones, causing symptoms such as weight loss, rapid heartbeat, and anxiety. Key therapy areas include diabetes medications, thyroid hormone disorder treatments, human growth hormone, testosterone replacement therapy, and others. These drugs are distributed through various channels, such as hospital pharmacies, online pharmacies, and retail pharmacies, and are used by a range of end users, including hospitals, ambulatory surgical centers, and more.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.